Visit LathamDrive – A new site with resources to help emerging companies grow.

Spencer B. Ricks

Boston Waltham | Boston
  • 1000 Winter Street
  • Suite 3700
  • Waltham, MA 02451
  • USA
 
 

Spencer Ricks advises entrepreneurs, start-ups, and emerging companies in the technology, life sciences, and energy sectors from formation through all stages of growth and beyond.

Mr. Ricks advises and guides companies throughout the entire corporate lifecycle, including in:

  • Early-stage formation and strategy
  • Venture capital financings
  • Other debt and equity financings
  • Employment matters
  • Commercial and strategic transactions
  • Securities law compliance
  • Mergers and acquisitions
  • Public offerings

He also regularly represents mature companies in strategic investments and commercial collaborations.

In addition to his practice, Mr. Ricks is involved in the local community, including representing, on a pro bono basis, asylum petitioners, U visa applicants, and survivors of domestic violence seeking refuge in the United States. He has also served as Massachusetts Chair of the J. Reuben Clark Law Society and as a member of the Boston Bar Association’s Private Equity & Venture Capital Conference Committee.

Mr. Ricks’s recent experience includes advising:

Life Sciences
  • T2 Biosystems, an in vitro diagnostic company, in its:
    • US$66 million initial public offering
    • US$34 million follow-on offering
    • US$40 million private offering to Canon
  • Fractyl Laboratories, a biotechnology company, in various corporate and strategic initiatives, including venture capital financings totaling more than US$150 million
  • IntelyCare, an on-demand, app-based healthcare staffing company, in various corporate and strategic initiatives, including venture capital financings totaling more than US$50 million
  • Lyra Therapeutics, a clinical-stage therapeutics company, in its US$30 million Series C financing prior to its initial public offering
  • Enko Chem, a crop protection technology company, in various corporate and strategic initiatives, including its US$45 million Series B financing
  • Invetx, a veterinary therapeutics company, in various corporate and strategic initiatives, including its US$25.5 million Series A financing
  • LifeVault (GoodCell), a biotechnology company, in various corporate and strategic initiatives, including its US$17.9 million Series Seed-2 financing
  • Omthera Pharmaceuticals, a pharmaceutical company, in its US$64 million initial public offering
Technology
  • ReliaQuest, a cybersecurity company, in its US$300 million growth financing led by KKR
  • Education.com, an education technology company, in its sale to IXL Learning
  • Teradyne, a supplier of automation equipment for testing and industrial applications, in its US$460 million private offering of Senior Convertible Notes
  • TravelPerk, a travel management software company, in various corporate and strategic initiatives, including early-stage and venture capital financings totaling more than US$130 million
  • Flowmill, a cloud network company, in various corporate and strategic initiatives, including its sale to Splunk
  • Cherre a real estate information technology company, in various corporate and strategic initiatives, including early-stage and growth financings totaling more than US$25 million
  • RealBlocks, an alternative investment technology platform, in various corporate and strategic initiatives, including early-stage and venture capital financings totaling more than US$7 million
  • Squadle, a customer logistics software company, in various financing, corporate, and strategic transactions
Energy
  • Form Energy, a long-duration energy storage technology company, in various corporate and strategic initiatives, including early-stage and venture capital financings totaling more than US$115 million
  • Syzygy Plasmonics, a chemical reactor technology company, in various financing, corporate, and strategic transactions
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.